Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- W. Marc Hertz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- -0.66
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -8.45
Financials
Revenue
$0.00-100.0%Net Income
$-1.64MEBITDA
$-1.65MFree Cash Flow
$-1.45MEPS (diluted)
$-0.91Shares Outstanding (diluted)
1.80M+202475.9%Operating Expenses
$1.65MCash & Debt
$10.95MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.96M | $-121.80 |
| 2024 | $0.00 | $-8.21M | $0.33 |
| 2023 | $0.00 | $-13.04M | $-140450.24 |
| 2022 | $0.00 | $-3.22M | $-47135.48 |
| 2021 | $0.00 | $-1.56M | $-2827.16 |
| 2020 | $100.0K | $-2.53M | $-4693.64 |
| 2019 | $0.00 | $-3.46M | $-660968.00 |
| 2018 | $0.00 | $-4.31M | $-822780.00 |
Valuation
GRIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been s…
View source ↗
Earnings
Fri, Nov 13(in 3 months)
Consensus estimate $-1.08 per share
Typical surprise -22.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.91 vs $-1.20beat
- Wed, May 13$-1.61 vs $-0.91miss
- Fri, Mar 13$-13.25 vs $-29.27beat
- Fri, Nov 14$-35.85 vs $-29.26miss
- Thu, Aug 14$-36.69 vs $-36.69beat
- Tue, Aug 12$-162.40 vs $-1.31miss
Estimates and results for GRI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GRI officers and directors.
No open-market trades in the recent filings. All 25 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
25 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.